Athenex gets closer to clinical trials in China

Athenex Inc. (Nasdaq:ATNX) has taken another step forward in its efforts to bring an oral breast cancer drug to market in Asia.   The Buffalo-based biopharmaceutical firm received an acceptance from the Chinese Food& Drug Administration for an investigational new drug (IND) application for Oraxol, an oral version of its oral formulation of the chemotherapy formulation paclitaxel. It’s the next in a series of okays from FDA groups across the world, including the United States, South America,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news